Brought to you by 
Abbott, GSK to develop diagnostic for NSCLC
03 Nov 2011
Executive Summary
Abbott Molecular and GlaxoSmithKline will ally in developing an automated polymerase chain reaction (PCR) test for non-small cell lung cancer (NSCLC).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott, GSK to develop diagnostic for NSCLC
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice